abstract: AIM: This study aims to determine the frequency of behaviour change and related factors generated in the population through the "Fighting Obesity Campaign" of the Turkish Ministry of Health. METHODS: Twelve statistical regions from NUTS-1 and 18 provinces were selected for the study sample. At least one province from each region was randomly selected, and stratawere defined as urban or rural. Of the sample selected, 2,038 respondents completed a face-to-face survey. Logistic regression analysis was used to analyse the data. Changing behaviour as result of the campaign was defined as the dependent variable. Behaviour change was defined as an individual taking at least one action to increase physical activity, calculate her/his Body Mass Index (BMI) or minimise meal portions. RESULTS: Of the sample selected, 84% of @entity1 lived in urban areas. Of total sample selected, 49.8% were @entity1 and 50.2% were @entity1 . According to BMI categorisation, 41.4% of @entity1 were underweight or normal weight, 34.3% were overweight and 24.3% were @entity28 . Of the total @entity1 , 85.2% learned about the "Fighting-Obesity Campaign" through television, 28.1% through radio, 11.0% from newspapers, 6.0% from billboards, and 19.2% from other sources. This study revealed that 28.5% of the @entity1 adopted desired behavioural changes after exposure to the campaign. Logistic regression results demonstrated that behaviour change is greater among @entity1 , individuals living in urban settings, group of @entity1 approving public spots, @entity28 individuals, and among the 20-39 age group. CONCLUSION: Media campaigns may cause behavioural changes by increasing motivation to prevent @entity28 within the target population. Con- tinuing these campaigns can lead to success at the national level.

title: Fighting XXXX campaign in Turkey: evaluation of media campaign efficacy.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'persons', 'men']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: BACKGROUND: Immunophenotyping has replaced cytochemical staining as the preferred technique for classifying @entity3052 . However, some @entity3052 ( @entity3052 ) lack lineage-associated markers. In our experience, @entity22252 ( @entity22252 ) is expressed in immature @entity235 monocytes. We hypothesized that @entity22252 is a useful marker for monocytic @entity3052 . OBJECTIVES: The objective was to compare @entity22252 expression in neoplastic cells from @entity235 with @entity706 , @entity1072 ( @entity1072 ), @entity981 ( @entity1619 ), and @entity3052 . METHODS: @entity22252 results were retrieved from medical records of @entity235 with @entity3052 . Smears from @entity235 with @entity706 or @entity1778 were also prospectively stained for @entity22252 activity. @entity1072 was based on persistent @entity6113 (10  *  10(9) /L) and @entity3052 on >=   20% blasts in blood or bone marrow. @entity1619 was classified based on positive phenotyping for T- or B-lymphocyte antigens, and @entity3052 on positive phenotyping for CD11b, CD11c or @entity31622 , or cytochemical staining for @entity2863 esterase, Sudan Black B, or myeloperoxidase. RESULTS: There was no @entity22252 activity in all 49 @entity706 and 7 CLLs. Weak @entity22252 activity was seen in 31% of 14 @entity1619 (all @entity1619 ). @entity22252 activity was seen in all 20 @entity3052 (P  <  .001 vs @entity1619 ) with strong activity in 64% (vs 25% @entity1619 ) in most neoplastic cells (median 75% vs 9% @entity1619 , P  =  .020). Of @entity3052 , 80% were @entity16129 + (vs 39% @entity1619 , P  =  .027) and 100% were MHCII- (vs 43% @entity1619 , P  =  .002). CONCLUSIONS: @entity22252 activity may be useful for @entity3052 confirmation in @entity235 , particularly if neoplastic cells only express @entity16129 + on immunophenotyping.

title: @entity22252 is a useful cytochemical marker for the diagnosis of acute myelomonocytic and XXXX in the @entity235 .

entities_list: @entity6113 :: ('MESH:D008218', 'Disease') :: ['lymphocytosis']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoid leukemia']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'lymphomas']

entities_list: @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphocytic leukemia']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemias', 'AML', 'acute leukemia']

entities_list: @entity2863 :: ('MESH:C006972', 'Chemical') :: ['chloroacetate']

entities_list: @entity22252 :: ('403548(Tax:9615)', 'Gene') :: ['Alkaline phosphatase', 'ALP', 'alkaline phosphatase']

answer: @entity1778 :: (MESH:D007938,Disease) :: ['monocytic leukemia']


abstract: OBJECTIVES: We present 2 @entity1 with free perforation of the anterior wall of the Roux limb due to marginal @entity1066 after an antecolic laparoscopic gastric bypass and describe the surgical management and laparoscopic repair technique. METHODS: A 15 mm Hg pneumoperitoneum was established with a Veress needle via the left subcostal approach in both @entity1 . Entrance into the abdomen was achieved with the 5 mm Optiview blunt trocar. The Genzyme liver retractor was used to lift the left lobe of the liver and expose the gastrojejunal @entity254 . A 30 degrees 5 mm telescope was used for visualization. In both cases, free fluid and purulent material were noted in the subdiaphragmatic region and along the right paracolic gutter, but the gastrojejunal anastomoses was intact. A 1 cm perforation with surrounding inflammatory exudate was identified on the anterior surface of the Roux limb distal to the gastrojejunostomy. The edges were debrided and intracorporeal 1-layer repair of the @entity1066 was performed with simple interrupted 2-0 Vicryl sutures. Fibrin glue was applied to the suture line and covered with an omental onlay patch. The @entity254 was tested with air insufflation and @entity6693 dye with no evidence of a leak. A Jackson-Pratt drain was placed in the left upper quadrant. RESULTS: Both @entity1 underwent an unremarkable hospital course, and follow-up EGD examination after 3 months revealed no evidence of @entity1066 . CONCLUSION: Laparoscopic exploration and the repair of the gastrointestinal perforations in @entity1 with a recent history of laparoscopic RYGBP is safe, if @entity1 are hemodynamically stable and present within the first 24 hours of the onset of symptoms.

title: Laparoscopic repair of a free perforation of a marginal XXXX after Roux-en-Y gastric bypass: a safe alternative to open exploration.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer', 'ulceration']

entities_list: @entity6693 :: ('MESH:D008751', 'Chemical') :: ['methylene blue']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

answer: @entity1066 :: (MESH:D014456,Disease) :: ['ulcer']


abstract: OBJECTIVES: (1) To collect, analyze and synthetize the evidence on @entity121 diagnosis as defined by Pope et al. and (2) To discuss its appropriate nosology and inclusion as a specific category in @entity146 classificatory systems. METHOD: A systematic search in the MEDLINE, the PsycNET, the LILACS and SciELO databases and in the International Journal of Eating Disorders was conducted looking for articles published between January 1997 and October 2014 and in EMBASE database between January 1997 and August 2013. Only epidemiological and analytical studies were considered for selection. The methodological quality of included studies was assessed according to the Evidence-Based Mental Health and the National Health and Medical Research Council's guidelines. The support for inclusion of @entity121 in @entity146 classificatory systems was examined against Blashfield et al.'s criteria. RESULTS: Thirty-four articles were considered eligible out of 5136. Most of the studies were cross-sectional and enrolled small, non-clinical samples. The methodological quality of all selected papers was graded at the lowest hierarchical level due to studies' designs. Forty-one percent of the publications considered the available evidence insufficient to support the inclusion of @entity121 in any existing @entity146 . The current literature does not fulfill Blashfield et al.'s criteria for the inclusion of @entity121 as a specific entity in @entity146 diagnostic manuals. CONCLUSION: The current evidence does not ensure the validity, clinical utility, nosological classification and inclusion of @entity121 as a new disorder in classificatory systems of @entity146 .

title: Systematic review of the diagnostic category XXXX .

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle dysmorphia']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders', 'psychiatric', 'category of psychiatric disorders']

answer: @entity121 :: (MESH:D009135,Disease) :: ['muscle dysmorphia']


abstract: @entity910 ( @entity910 ) is a genetically heterogeneous @entity74 arising from @entity4423 of motile cilia and sperm. This is associated with a variety of ultrastructural defects of the cilia and sperm axoneme that affect movement, leading to clinical consequences on respiratory-tract mucociliary clearance and lung function, fertility, and left-right body- @entity2270 determination. We performed whole-genome SNP-based linkage analysis in seven consanguineous families with @entity910 and central-microtubular-pair abnormalities. This identified two loci, in two families with intermittent absence of the central-pair structure (chromosome 6p21.1, Zmax 6.7) and in five families with complete absence of the central pair (chromosome 6q22.1, Zmax 7.0). Mutations were subsequently identified in two positional candidate genes, @entity70263 on chromosome 6p21.1 and @entity70264 on chromosome 6q22.1. Haplotype analysis identified a common ancestral founder effect @entity70264 mutation present in UK-Pakistani pedigrees. Both @entity70263 and @entity70264 encode protein components of the axonemal radial spoke head. In situ hybridization of @entity19 @entity70265 shows gene expression restricted to regions containing motile cilia. Investigation of the effect of knockdown or mutations of @entity70263 orthologs in @entity3392 and Chlamydomonas indicate that radial spoke head proteins are important in maintaining normal movement in motile, "9+2"-structure cilia and flagella. This effect is rescued by reintroduction of gene expression for restoration of a normal beat pattern in @entity3392 . Disturbance in function of these genes was not associated with defects in @entity2270 in @entity1 or @entity3392 .

title: Mutations in radial spoke head protein genes XXXX and @entity70264 cause primary @entity910 with central-microtubular-pair abnormalities.

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['PCD', 'Primary ciliary dyskinesia']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['inherited disorder']

entities_list: @entity2270 :: ('MESH:C566610', 'Disease') :: ['left-right axis determination', 'axis']

entities_list: @entity4423 :: ('MESH:D015154', 'Disease') :: ['dysmotility']

answer: @entity70263 :: (558005(Tax:7955),Gene) :: ['RSPH9']


abstract: PURPOSE: Recently, @entity1749 has been used to treat @entity465 ( @entity465 ) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when @entity1749 was used to treat refractory @entity465 . MATERIALS AND METHODS: Eleven refractory @entity465 episodes treated with @entity1749 were included in this study. The @entity1 received one or two cycles of @entity1749 (1.3 mg/m  ) on days 1, 4, 8, and 11. RESULTS: @entity1749 effectively reduced antibodies against various targets, including human leukocyte antigen (HLA) class I and II, @entity7743 . Antibodies were depleted or reduced significantly in eight @entity465 episodes. Overall, there was a significant improvement in the mean estimated glomerular filtration rate (eGFR) at 3 months after therapy (36.91  22.15 mL/ @entity1009 .73 m  ) versus eGFR at time of @entity465 diagnosis (17.00  9.25 mL/ @entity1009 .73 m  ; p=0.007). All six early-onset @entity465 episodes (within 6 months post-transplantation) showed full recovery of allograft function. Additionally, three of the five late-onset @entity465 episodes (>6 months post-transplantation) showed improved allograft function. CONCLUSION: Anti-humoral treatment based on @entity1749 might be an effective strategy against refractory @entity465 caused by various types of antibodies. Notably, this treatment could be more effective in early-onset @entity465 than in late-onset @entity465 .

title: The Effect of XXXX on Antibody-Mediated Rejection after Kidney Transplantation.

entities_list: @entity465 :: ('MESH:D007153', 'Disease') :: ['AMR', 'antibody-mediated rejection']

entities_list: @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib', 'Bortezomib']

entities_list: @entity7743 :: ('185', 'Gene') :: ['ABO blood group antigen, and angiotensin II type 1 receptor']

answer: @entity1749 :: (MESH:C400082,Chemical) :: ['Bortezomib']


abstract: BACKGROUND: @entity99 have been described in @entity8404 ( @entity8404 ) in isolated case reports, and most of these have been reported to be @entity157 . OBJECTIVES: The aim of the present study was to determine the frequency, imaging, and histopathologic characteristics of @entity99 in @entity1 with @entity8404 . METHODS: Available abdominal imaging of @entity1 with @entity8404 was retrospectively reviewed to note the presence of any focal @entity409 , its location, and imaging characteristics. Other findings including signs of @entity101 , portal lymph nodes, and splenic and @entity8 were also noted. Findings were correlated with pathology in available cases and with clinical follow-up. RESULTS: Of 55 @entity1 with clinically and/or genetically confirmed @entity8404 followed in the liver clinic, 39 (19 @entity1 , 20 @entity1 ; mean age 8.9 years) with imaging available on picture archival and communication system were included in the study. Focal @entity99 were seen in 12 of the 39 (30%) @entity1 , solitary in 11 and multiple in 1. Ten of these @entity1 had a large nodule adjacent to the right portal vein. The median diameter of the lesions was 8.1 cm (range 5.6-9.8 cm). Magnetic resonance imaging features and pathology in available cases were suggestive of a regenerative nodule. a-fetoprotein levels were normal in all except 1 @entity1 who had mild elevation. CONCLUSIONS: Combining our series and previous case reports, the presence of a large nodule adjacent to the right portal vein appears to be a common finding in @entity8404 . The typical location, normal a-fetoprotein levels, and magnetic resonance imaging features with vessels coursing through the lesion can reliably differentiate this benign nodule from @entity157 .

title: Solitary Hepatic Nodule Adjacent to the Right Portal Vein: A Common Finding of XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['child', 'children', 'girls', 'boys']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal abnormalities']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['portal hypertension']

entities_list: @entity8404 :: ('MESH:D016738', 'Disease') :: ['Alagille syndrome', 'ALGS']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver lesion']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic lesions', 'Hepatic lesions']

answer: @entity8404 :: (MESH:D016738,Disease) :: ['Alagille Syndrome']


abstract: OBJECTIVE: The A/J and C57BL/6J @entity19 strains differ markedly in their exploratory behavior and their weight gain on a high-fat diet. We examined the genetic contributions of exploratory behavior to body weight and tested for shared, pleiotropic loci influencing energy homeostasis. RESEARCH METHODS AND PROCEDURES: Segregating (AxB6)F2 intercross (n = 514) and (B6AF1xA/J)N2 backcross (N = 223) populations were studied, phenotyping for weight and exploratory behaviors. Relationships among traits were analyzed by correlations. Weight traits were dissected with a genome-wide scan. RESULTS: Modest correlations were found between exploratory behaviors and weight, explaining 2% to 14% of the variance. Quantitative trait loci (QTL) for body weight at 8 weeks (wgt8), 10 weeks (wgt10), and 2-week weight gain (difference between weeks 8 and 10) on a 6% fat diet were mapped. Two QTL on chromosome 1 (peaks at 66 cM and 100 cM; @entity70360 ) affected wgt8 [likelihood of the odds ratio (Lod), 3.0 and 4.4] and wgt10 (Lod, 2.2 and 3.4), respectively. In the backcross, a significant QTL on chromosome 4 (peak at 66 cM; @entity70361 ) affected wgt 8 (Lod, 3.3) and wgt10 (Lod, 3.1). For 2-week weight gain, suggestive QTL were mapped on chromosomes 4 and 6. The chromosome 6 QTL region overlaps a @entity1 7q locus for @entity28 . A search for between-strain sequence polymorphisms in the leptin and NPY genes was unrevealing. DISCUSSION: In @entity19 , loci influencing exploratory activity play a modest role in body-weight regulation. Some forms of @entity28 may emerge from loci regulating normal body weight.

title: Genetic contributions to body weight in XXXX : relationship of exploratory behavior to weight.

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: The efficacy of both preliminary and continuous hemodialysis during extracorporeal circulation (ECC) was evaluated in the pediatric population. Preliminary hemodialysis of the priming solution was initiated in eight @entity1 ( @entity2033 -I group), while both preliminary and continuous hemodialysis during ECC was performed in another eight @entity1 ( @entity2033 -II group). The control group which consisted of eight @entity1 did not undergo hemodialysis. Urine volume during ECC, perfusion pressure, and water balance were measured and compared among the three groups. In the @entity2033 , the total urine volume during ECC was greater than in control group, but there was no significant difference. In the control group, the perfusion pressure temporally decreased after the pump was operating for five minutes, but the perfusion pressures remained stable in the @entity2033 . Therefore, preliminary hemodialysis appears to prevent the "initial drop" seen in perfusion pressures. Water balance in the control group tended to be in positive balance, but both the @entity2033 appeared to be in negative balance. Significant differences between @entity2033 -I and @entity2033 -II in contrast to the control group (p < 0.05) and p < 0.04, respectively) were observed. Preliminary hemodialysis is useful during ECC in @entity1 and @entity1 because by maintaining perfusion pressure urine output remains adequate while a net negative water balance is achieved. Preliminary hemodialysis will increase the continuous hemodialysis in @entity1 who are subjected to prolonged extracorporeal circulation.

title: [Role for preliminary and continuous hemodialysis during extracorporeal circulation in @entity1 and XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['infants', 'children']

entities_list: @entity2033 :: ('MESH:D006816', 'Disease') :: ['HD-I and HD-II groups', 'HD']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: We describe a method for evaluating the value of increased cost of pharmacological augmentation that, taken for 6 weeks, accelerates the action of an antidepressant. We test the hypothesis that, if onset of action is taken into account, any added direct costs of the augmenting agent are offset by longer term cost effectiveness. Data to illustrate the method were based on a double-blind randomized placebo controlled study, in which 80 @entity1 originally took part. @entity1 received the selective @entity750 reuptake inhibitor (SSRI) antidepressant @entity903 and an augmenting agent ( @entity7690 ) or placebo. After 6 weeks, @entity1 were offered SSRI alone on an open label basis for up to 6 months. At that point they were discharged to their general practitioner or local psychiatric services and subsequently assessed by us at one year. We have used techniques of decision analysis, cost effectiveness and cost benefit and have included a sensitivity analysis. The direct costs over one year of SSRI and augmenting agent, if taking the acceleration effect into account, represented greater cost effectiveness than the SSRI antidepressant alone. The cost effectiveness analysis was positive in both cases. We conclude that the direct costs of treatment are higher than those of previous calculated with SSRIs; but the rate of onset must be taken into account. The application of the model appears valid and useful, and may be used as part of the evaluation of other augmentation regimes.

title: Cost effectiveness study of a year follow-up of selective XXXX reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity7690 :: ('MESH:D010869', 'Chemical') :: ['pindolol']

entities_list: @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine']

entities_list: @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']

answer: @entity750 :: (MESH:D012701,Chemical) :: ['serotonin']


abstract: PURPOSE: Numerous studies, including those using animal models of @entity1714 development and @entity1 clinical trials, have shown that the non-selective muscarinic antagonist @entity3897 is effective in preventing the axial elongation that leads to @entity1714 development. Among all of the muscarinic @entity934 receptors (mAChRs), @entity70534 (M1) was the most effective in preventing @entity735 . Our specific aim in this study was to examine the association between @entity1714 and polymorphisms within the muscarinic @entity934 receptors 1 gene ( @entity19291 ). METHODS: The @entity1 comprised of a @entity1714 group (n=194; age range, 17-24 years) having a myopic spherical equivalent greater than 6.5 diopters (D) and a control group (n=109; age range, 17-25 years) having a myopic spherical equivalent less than 0.5 D. Genotyping was performed using an assay-on-demand allelic discrimination assay. Polymerase chain reaction (PCR) was performed using 96 well plates on a thermal cycler. The polymorphisms detected were S1 ( @entity19291 rs11823728), S2 ( @entity19291 rs544978), S3 ( @entity19291 rs2186410), and S4 ( @entity19291 rs542269). RESULTS: There was a significant difference in the distribution of S2 and S4 between the @entity1714 and control groups (p=2.40 x 10(-6) and 2.38 x 10(-8), respectively). The odds ratios of AA genotype of S2 and GG genotype of S4 were both 0.08 (95% confidence interval [CI]: 0.02-0.29 and 0.02-0.36, respectively). Logistic regression test revealed S1, S2, and S4 @entity19291 as all being significant in the development of @entity1714 . Moreover, the distributions of haplotype 4 (Ht4; C/A/A/A) differed significantly between the two groups (p=3.4 x 10(-5), odds ratio: 0.1, 95% CI: 0.03-0.34). CONCLUSIONS: Our results suggest that the S2 and S4 polymorphisms of @entity19291 are associated with susceptibility for developing @entity1714 . S1, S2, and S4 @entity19291 had a co-operative association with @entity1714 .

title: Muscarinic @entity934 receptor 1 gene polymorphisms associated with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'human']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['myopic eye change']

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['atropine']

entities_list: @entity1714 :: ('MESH:D009216', 'Disease') :: ['high myopia', 'myopia']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity1714 :: (MESH:D009216,Disease) :: ['high myopia']


abstract: BACKGROUND AND OBJECTIVES: Although not well known, @entity6413 ( @entity6413 ) is an important cause of @entity615 , which may lead to decreased quality of life, disability and @entity74 . This study aimed to evaluate the clinical characteristics and prevalence of @entity6413 , to estimate its impact on the quality of life and to determine its association with @entity148 , @entity308 and disability in @entity1 at public hospitals in S  o Lu  s, MA. METHODS: Cross-sectional, descriptive and analytical study. Eighteen @entity1 characterized as having @entity6413 were selected, and their clinical, epidemiological and psychological characteristics, their quality of life and their levels of physical fitness were evaluated through clinical evaluations, Beck questionnaires, the Short Form-36 (SF-36), the Rolland-Morris questionnaire and the Douleur Neurophatique 4 questions. The multidimensional @entity158 evaluation was performed using the McGill Pain Questionnaire. RESULTS: The prevalence of post-laminectomy @entity158 was 60  %. Most of the @entity1 assessed in this study were male and received a family income of up to minimum wage; their mean age was 45  years. All of the @entity1 presented with chronic, intense @entity158 that had lasted an average of 7.22  years. The prevalence of @entity9 was 89.9  %. The physical appearance and functional capacity domains of the SF-36 were classified as unsatisfactory in 94.4 and 83.3  % of the @entity1 , respectively. None of the @entity1 exhibited high levels of physical fitness. The average score was 21.33 for @entity148 and 18.88 for @entity308 . There was a strongly positive and significant relationship between the @entity148 and @entity308 scores. Additionally, there was a moderately positive and significant relationship between the disability and @entity148 scores. Regarding the correlation between the @entity158 intensity and the quality of life, there was a moderately significant relationship between the @entity1 ' mental health and their vitality. CONCLUSION: @entity6413 exhibits a high prevalence and significance, and it causes high levels of morbidity in @entity1 . Furthermore, @entity6413 features intense levels of @entity158 , reduced quality of life and greater physical and occupational disability.

title: Clinical evaluation of the XXXX in public hospitals in the city of S  o Lu  s, Brazil.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['chronic back pain']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['psychological disorders']

entities_list: @entity6413 :: ('MESH:D038223', 'Disease') :: ['post-laminectomy syndrome', 'PLS']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']

answer: @entity6413 :: (MESH:D038223,Disease) :: ['post-laminectomy syndrome']


abstract: BACKGROUND: The treatment of @entity1744 ( @entity1744 ) is a challenge because its cause remains unknown. Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 ( @entity38349 ) in @entity1 with @entity1744 showed inconsistent findings. This study aimed to assess the combined effect of @entity38349 on reducing symptom severity of @entity1744 based on the published data. METHODS: A meta-analysis was conducted using fixed-effect models to estimate the combined effect of @entity38349 on primary outcomes, which included @entity490 , @entity11035 /distention, and bowel habit satisfaction. A systemic review was performed based on PubMed, Cochrane Library, and EMBASE databases to identify the randomized controlled trials comparing probiotics @entity38349 with placebo in treating @entity1744 symptoms, published up until December 31, 2016. Standardized mean differences (SMD) method was used to combine data since scales to measure the efficacy of probiotics were different among studies. RESULTS: A total of five studies were identified as suitable for inclusion, including three studies with single probiotic @entity38349 and two studies with composite probiotics containing @entity38349 . Treatment with single probiotic @entity38349 didn't impact on @entity490 , @entity11035 /distention, or bowel habit satisfaction among @entity1744 @entity1 . However, @entity1 who received composite probiotics containing @entity38349 significantly reduced @entity490 (SMD, 0.22; 95%CI, 0.03-0.41) and @entity11035 /distention (SMD, 0.30; 95%CI, 0.04-0.56). After combining the data from six studies, the improvement of @entity11035 /distention among @entity1744 @entity1 remained significant (SMD, 0.21; 95%CI, 0.07-0.35). CONCLUSION: Composite probiotics consisting of @entity38349 might be an effective therapeutic option to @entity1744 @entity1 , which could significantly alleviate the symptoms of @entity1744 without significant adverse effects. However, the efficacy of single probiotic @entity38349 on @entity1744 has not been confirmed yet, which needs to be further validated by more large-sized randomized clinical trials.

title: Efficacy of Bifidobacterium infantis 35624 in XXXX with @entity1744 : a meta-analysis.

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome', 'IBS']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: @entity75 ( @entity75 ) is the chronic electrical stimulation of selected target sites in the brain through stereotactically implanted electrodes. More than 150 000 @entity1 around the world have been treated to date with @entity75 for medically intractable conditions. The indications for @entity75 include @entity717 , @entity302 , and some types of @entity1032 . METHODS: This review is based on relevant publications retrieved by a selective search in PubMed and the Cochrane Library, and on the current guidelines of the German Neurological Society (Deutsche Gesellschaft f  r Neurologie, DGN). RESULTS: @entity75 is usually performed to treat @entity16 , most often @entity717 and, in particular, @entity191 . Multiple randomized controlled trials (RCTs) have shown that @entity75 improves @entity400 , @entity910 , and quality of life in @entity1 with @entity191 by 25% to 50%, depending on the rating scales used. @entity75 for @entity400 usually involves stimulation in the cerebello-thalamo-cortical regulatory loop. In an RCT of @entity75 for the treatment of @entity3520 , the @entity1 who underwent @entity75 experienced a 39.3% improvement of @entity3519 , compared to only 4.9% in the control group. Two multicenter trials of @entity75 for @entity308 were terminated early because of a lack of efficacy. CONCLUSION: @entity75 is an established treatment for various neurological and @entity146 . It has been incorporated in the DGN guidelines and is now considered a standard treatment for advanced @entity191 . The safety and efficacy of @entity75 can be expected to improve with the application of new technical developments in electrode geometry and new imaging techniques. Controlled trials would be helpful so that @entity75 could be extended to further indications, particularly @entity146 ones.

title: Deep Brain Stimulation in Neurological and XXXX .

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental illness']

entities_list: @entity3520 :: ('MESH:D020821', 'Disease') :: ['primary generalized dystonia']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric', 'psychiatric diseases']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Deep brain stimulation', 'DBS']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological diseases']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['dyskinesia']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease"]

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['movement disorders']

answer: @entity146 :: (MESH:D001523,Disease) :: ['Psychiatric Disorders']


abstract: OBJECTIVES: To test the feasibility of using an electronic medical record (EMR)-based @entity262 ( @entity262 ) that incorporates morbidity and frailty information to individualize @entity14 ( @entity14 ) screening recommendations. STUDY DESIGN: Our framework used the payoff time, defined as the minimum time until the benefits of screening exceed the harms. METHODS: Subjects were 24 @entity1 eligible for @entity14 screening and 22 primary care providers (PCPs). Measures included @entity4426 satisfaction with existing reminder systems and with decision support. RESULTS: The run-in phase, during which the intervention was inactive but its performance was verified, had 14 @entity1 enrolled. The intervention phase, during which payoff time and life expectancy calculations were used to recommend for or against @entity14 screening, had 10 @entity1 enrolled. Of the 10 @entity1 enrolled in the intervention phase, the @entity262 recommended in favor of @entity14 screening for 6 @entity1 . (The PCPs also recommended it for those 6 @entity1 , although 3 refused the screening.) The @entity262 recommended against @entity14 screening for 4 @entity1 , while the PCPs recommended against it for 3 of those 4 and ordered the screening for 1 @entity1 . PCPs who had @entity1 enrolled in the intervention phase indicated interest in having payoff time information for all @entity1 eligible for @entity14 screening. This pilot study was small and was not powered to determine the effect of the intervention on screening behavior. CONCLUSIONS: @entity14 screening involves balancing immediate harms with longer-term benefits; EMR decision support may facilitate personalized benefit/harm assessment. The payoff time framework is feasible for implementation in EMR decision support.

title: Pilot of decision support to individualize XXXX screening recommendations.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['DSS', 'decision support system']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'CRC', 'colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: BACKGROUND: In 1992, the International Agency for Research on @entity5 (IARC) classified @entity4197 mists as @entity1 carcinogen, based primarily on @entity1 data showing increased risk for @entity5 . Uncertainties still exist about other @entity5 . OBJECTIVES: We carried out a historical mortality study among workers ofa plant producing @entity4197 in Tuscany, Italy. METHODS: We reconstructed a cohort of 1372 male and 37female workers with at least one year of employment at the plant in the period 1962-97; 46% ofthe workers had previously been working in @entity42524 mines in the area where rocks have a high @entity3440 content. Environmental measurements of @entity4197 and @entity12546 from the 1970's were generally below the TLVs. Mortality was investigated as of August 2000; Standardized Mortality Ratios (SMR) were calculated using Tuscany reference rates. RESULTS: Overall mortality was below expectation (SMR 77). In labourers, @entity5 deaths were 4 vs 3.1 expected (SMR 130, 95% CI 35-333), while mortality from @entity2 was below expectation (27/32.8, SMR 82, 95% CI 54-120). An @entity1778 was observed mainly in workers without previous experience in mines (3/0.6, SMR 523, 95% CI 108-1527). Mortality from silicosis, but not from @entity2 , was remarkably high among workers with previous employment in mines. CONCLUSIONS: Among workers employed in @entity4197 production, with or without previous experience in mines, we did not observe increased mortality from @entity2 . The increased mortality from @entity1778 cannot be attributed to any of the exposures documented in the study plant and requires further investigation.

title: [Mortality study in a cohort of workers employed in a plant producing XXXX ].

entities_list: @entity12546 :: ('CHEBI:18422', 'Chemical') :: ['sulphur dioxide']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['larynx cancer', 'respiratory cancers', 'Cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['larynx or lung cancer', 'lung cancer']

entities_list: @entity4197 :: ('CHEBI:26836', 'Chemical') :: ['sulphuric acid']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['myeloid leukaemia', 'excess of myeloid leukaemia']

answer: @entity4197 :: (CHEBI:26836,Chemical) :: ['sulphuric acid']


abstract: UNASSIGNED: 55 Background: Young @entity4479 (YAS) are at risk for side effects of @entity5 therapy and poor post treatment self-management relative to older @entity4479 ( @entity4479 ). Survivorship care plans (SCPs) have proved feasible to provide education on symptom management, but the characteristics of YAS who utilize SCPs and @entity1 -reported outcomes (PROs) of YAS via SCPs remains unstudied. METHODS: @entity1 -reported characteristics and outcomes of YAS, age 18 to 39 years, who used a free online @entity17938 generator (OncoLife), between May 2010 and May 2012 are reported. PROs of YAS were compared to @entity4479 , age 40-70 years, via frequencies and chi-squared analyses. PROs were queried upon generation of @entity17938 based on diagnosis and treatments received. RESULTS: YAS (n = 1,445, Mage= 31.5 years) and @entity4479 (n = 6301, Mage= 56.3 years) were primarily female (69% vs. 78%), Caucasian (76% vs. 86%) and an average of 2.6 years (range 0-20years) vs. 3.2 years (range 0-46 years) since diagnosis and treatment. Most common diagnoses were @entity0 , @entity5 , @entity706 , @entity259 , and @entity242 in YAS vs. breast, colon, @entity706 , prostate, and @entity2 in @entity4479 . Three-quarters (75%) of YAS and 70% of @entity4479 generated the @entity17938 themselves with the remaining SCPs generated by health care providers. Less than a quarter (22%) of YAS or @entity4479 (18%) reported previously receiving a treatment summary. The most commonly endorsed PROs in YAS and @entity4479 were neurocognitive changes and fatigue. Fewer YAS than @entity4479 endorsed pulmonary concerns and male sexual side effects. The majority of PROs were reported at similar proportions by YAS and @entity4479 (see table). CONCLUSIONS: In @entity1 who generated an OncoLife @entity17938 , YAS reported similar rates of treatment-related side effects to those reported by @entity4479 demonstrating SCPs as a mechanism to capture and address off-therapy issues for all survivors. [Table: see text].

title: Use of online survivorship care plans by young adult @entity5 survivors: @entity1 characteristics and XXXX reported outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity4479 :: ('MESH:C538052', 'Disease') :: ['AS', 'adult survivors']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['testicular cancer', 'cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: UNASSIGNED: @entity1313 cells invade adjacent normal brain along white matter (WM) bundles of axons. We therefore hypothesized that the location of @entity5 intersecting WM tracts would be associated with differing survival. This study introduces a method, voxel-wise survival analysis (VSA), to determine the relationship between the location of @entity1313 intersecting WM tracts and @entity1 prognosis. 113 @entity463 ( @entity463 ) @entity1 were retrospectively analyzed for this study. @entity1 specific @entity5 location, defined by contrast-enhancement, was combined with diffusion tensor imaging derived tractography to determine the location of axons intersecting @entity5 enhancement (AXITEs). VSA was then used to determine the relationship between the AXITE location and @entity1 survival. @entity5 intersecting the right anterior thalamic radiation (ATR), @entity75 (IFOF), right and left cortico-spinal tract (CST), and corpus callosum (CC) were associated with decreased overall survival. @entity5 intersecting the CST, body of the CC, right ATR, posterior IFOF, and @entity75 are associated with decreased progression-free survival (PFS), while @entity5 intersecting the right genu of the CC and anterior IFOF are associated with increased PFS. @entity1 with @entity5 intersecting the ATR, IFOF, CST, or CC had significantly improved survival prognosis if they were additionally treated with bevacizumab. This study demonstrates the usefulness of VSA by locating AXITEs associated with poor prognosis in @entity463 @entity1 . This information should be included in @entity1 -physician conversations, therapeutic strategy, and clinical trial design.

title: Location of XXXX intersecting white matter tracts predicts @entity1 prognosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Patient']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor', 'Brain tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumors', 'tumors']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['inferior longitudinal fasciculus', 'right inferior fronto-occipital fasciculus']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM', 'primary glioblastoma']

answer: @entity1313 :: (MESH:D001932,Disease) :: ['brain tumor']


abstract: OBJECTIVE: To compare the long-term real-world outcomes of consecutive @entity1 with unprotected left main @entity453 (ULMCA) underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and coronary artery bypass grafting (CABG). METHODS: Consecutive @entity1 with ULMCA (defined as stenosis >=  50%) undergoing DES implantation or CABG between January 2003 to July 2009 in Beijing Anzhen Hospital were enrolled. The follow-up period extended through August 2013. The end points of the study were @entity204 , @entity204 , repeat revascularization, @entity583 ( @entity583 ), @entity64 , the composite of @entity204 , @entity583 or @entity64 and MACCE (major adverse cardiac and cerebrovascular events, the composite of @entity204 , @entity583 , @entity64 or repeat revascularization). RESULTS: From January 2003 to July 2009, 922 ULMCA @entity1 were enrolled in this study (465 PCI @entity1 , and 457 CABG @entity1 ). The median follow-up was 7.1 years (interquartile range 5.3 to 8.2 years). The crude relative risk was as follows: overall @entity204 rate (13.0% (41/465) vs. 22.1% (72/457), P = 0.009), @entity64 rate (5.8% (11/465) vs. CABG 18.9% (46/457), P < 0.001) were significantly lower whereas the rate of repeat revascularization (32.3% (110/465) vs. CABG 19.2% (58/457), P < 0.001) was significantly higher in PCI group than in CABG group. @entity583 rate was similar between PCI and CABG group (13.9% (33/465) vs. 6.7% (26/457), P = 0.196). MACCE rate was also similar between the 2 groups (42.9% (145/465) vs. 42.5% (142/457), P = 0.122). After multivariate adjusting, there was no significant difference in rates of @entity204 , @entity583 and a composite of serious outcomes ( @entity204 , @entity583 , or @entity64 ) between the 2 groups. Rates of MACCE were significantly higher in the PCI group (P = 0.009) due to increased rate of repeat revascularization (P < 0.001). However, @entity64 rate was still significantly higher in CABG group (P = 0.001) after multivariate adjusting. CONCLUSION: During a follow-up up to 8.2 years, the survival rate is similar between the PCI and the CABG group in @entity1 with @entity453 . The rate of repeat revascularization is significantly higher and @entity64 rate is significantly lower in the PCI group compared to CABG group.

title: [Long-term outcomes of @entity1 with unprotected left main XXXX post revascularization].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['ULMCA disease', 'coronary artery disease']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death', 'death']

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']


abstract: OBJECTIVE: To determine whether @entity1 with pallid breath-holding spells associated with @entity1168 can be treated safely and successfully with permanent pacemaker implantation. METHODS: The records of pediatric @entity1 who had apparent breath-holding spells and associated @entity1168 and were treated with permanent pacemaker implantation were reviewed. RESULTS: Ten pediatric @entity1 with apparent breath-holding spells associated with @entity1168 were treated with a permanent ventricular demand pacemaker at the Mayo Clinic between 1985 and 1995. @entity1 had onset of symptoms between ages 6 days and 12 months and presented for evaluation between ages 12 months and 5 years. Duration of spells was 15 seconds to 10 minutes. Medications to prevent spells were unsuccessful. Electrocardiograms documented asystolic pauses of 1.7 to 24 seconds (mean: 11.9 seconds). Permanent ventricular demand pacemakers were implanted at 10 months to 5 years of age (median: 14.5 months): 9 endocardial and 1 epicardial. Three @entity1 required pacemaker revision. At follow-up of 38 to 170 months (median: 65.5), 5 @entity1 had complete resolution of spells, 2 had only mild color change without loss of consciousness or @entity410 activity, and 3 continued to have minor brief spells. CONCLUSIONS: Permanent pacemaker therapy for @entity1 with pallid breath-holding spells associated with severe @entity1168 is safe, efficacious, and warranted.

title: Breath-holding spells associated with significant XXXX : successful treatment with permanent pacemaker implantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

answer: @entity1168 :: (MESH:D001919,Disease) :: ['bradycardia']


abstract: @entity26 free radicals (OFRs) are associated with ischaemia-reperfusion injury involving many organs, including the heart, which can lead to @entity308 in the cardiac ultrastructure. This is seen upon the release of the aortic crossclamp when the ischaemic myocardium is reperfused in @entity1 undergoing cardiopulmonary bypass (CPB). Various studies have shown that by adding OFR scavenging agents or antioxidants to the CPB prime or cardioplegia, cardiac performance improves. @entity2656 is an osmotic diuretic with free radical scavenging properties, which has been shown to reduce the extent of @entity130 and improve the function of the myocardium. This study evaluated how effective @entity2656 is as an OFR scavenger by administering different concentrations of cardioplegia antegrade into the aortic root, thus maximising its effects directly upon the myocardium rather than being diluted in the CPB prime. Thirty-three @entity1 undergoing primary coronary artery bypass grafting (CABG) were, by double blind random selection, allocated into one of three groups: group 1, a control group (consisting of 11 @entity1 ) receiving no @entity2656 ; group 2 (11 @entity1 ), receiving a concentration of 4 g/l; and group 3 (11 @entity1 ), receiving 8 g/l. Three blood samples were taken directly from the coronary sinus during bypass: the first sample at the start of bypass, just prior to the crossclamp being applied; the second sample just after removal of the crossclamp; and the third sample just prior to termination of bypass. All samples were then centrifuged and the plasma analysed for @entity1234 ( @entity1865 ) using high-performance liquid chromatography (HPLC). @entity1865 , an endproduct of lipid peroxidation, causes cellular damage and disruption of cell membranes when tissue antioxidants are exhausted. The more @entity1865 produced, the greater the depletion of tissue antioxidants secondary to OR formation during reperfusion when the aortic crossclamp is removed. HPLC is a useful biochemical study; however, it is not a direct indicator of @entity308 , such as an invasive test would be, and this should be borne in mind. Statistically, the results do not show a significant difference among the three groups or among the three samples. However, a trend can be seen, which shows lower levels of @entity1865 in the two groups receiving @entity2656 and there is an indication of a rise in @entity1865 levels upon the start of reperfusion in the two groups receiving @entity2656 , but not the control group. It is concluded that further samples would be needed to find a significant difference in @entity1865 concentrations.

title: @entity2656 in cardioplegia as an @entity26 free radical scavenger measured by XXXX .

entities_list: @entity2656 :: ('MESH:D008353', 'Chemical') :: ['Mannitol', 'mannitol']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressed myocardial function', 'depressed cardiac function and abnormalities']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['Oxygen']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['ischaemic injury']

answer: @entity1234 :: (MESH:D008315,Chemical) :: ['malondialdehyde']


abstract: BACKGROUND: @entity11037 ( @entity11037 ) is an important postoperative problem with an incidence of 20% to 35% especially prevalent after the removal of mandibular molars. Fibrinolysis with subsequent loss of @entity4461 is believed to be the general cause of @entity11037 . OBJECTIVES: This study aims to evaluate the efficacy of @entity927 , an antifibrinolytic agent in comparison with a placebo with respect to the reduction of incidence of @entity11037 after the extraction of mandibular molars by using following parameters: @entity158 , disintegration of Clot, @entity7868 . MATERIALS AND METHODS: A double blind study consisted of 60 @entity1 , who underwent routine dental extractions of mandibular molar teeth. Group A (30 @entity1 ) requiring routine dental extractions of mandibular teeth was randomly selected and was administered a dose of @entity927 orally (Pause 500mg) one hour prior to extraction of teeth. Gel foam soaked in @entity927 (160mg) was placed into the extraction socket postoperatively. A figure of eight silk suture was placed over the socket to secure the gelfoam. Group B (30 @entity1 ); a placebo ( @entity24149 ) was given orally one hour prior to the extraction and gel foam soaked in saline was placed into the extraction socket postoperatively. A figure of eight silk suture was placed over the socket. @entity158 was rated individually by each @entity1 at 3(rd), 7(th), 14(th) day after extraction and the results was statistically analysed. RESULTS: This study supports that the use of @entity927 both locally and systemically following the removal of the teeth reduces the incidence of @entity11037 associated with the extraction of mandibular molars. CONCLUSION: @entity927 has several advantages also when used for simple dental extractions, namely: low cost and ready availability and therefore we recommend this treatment modality.

title: The Efficacy of XXXX in the Reduction of Incidence of Dry Socket: An Institutional Double Blind Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity7868 :: ('MESH:D006209', 'Disease') :: ['halitosis']

entities_list: @entity11037 :: ('MESH:D004368', 'Disease') :: ['Alveolar osteitis', 'AO']

entities_list: @entity4461 :: ('MESH:D020141', 'Disease') :: ['blood clotting']

entities_list: @entity927 :: ('MESH:D014148', 'Chemical') :: ['tranexamic acid', 'Tranexamic acid']

answer: @entity927 :: (MESH:D014148,Chemical) :: ['Tranexamic Acid']


abstract: In budding @entity375 , actin disruption prevents nuclear division. This has been explained as activation of a morphogenesis checkpoint monitoring the integrity of the actin cytoskeleton. The checkpoint operates through inhibitory @entity669 phosphorylation of @entity11869 , the budding @entity375 Cdc2 homolog. Wild-type @entity6739 cells also arrest before mitosis after actin depolymerization. Oversized cells, however, enter mitosis uninhibited. We carried out a careful analysis of the kinetics of mitotic initiation after actin disruption in undersized and oversized cells. We show that an inability to reach the mitotic size threshold explains the arrest in smaller cells. Among the regulators that control the level of the inhibitory Cdc2-Tyr15 phosphorylation, the Cdc25 protein @entity669 phosphatase is required to link cell size monitoring to mitotic control. This represents a novel function of the Cdc25 phosphatase. Furthermore, we demonstrate that this cell size-monitoring system fulfills the formal criteria of a cell cycle checkpoint.

title: G2/M arrest caused by actin disruption is a manifestation of the cell size checkpoint in XXXX .

entities_list: @entity6739 :: ('4896', 'Species') :: ['Schizosaccharomyces pombe']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity6739 :: (4896,Species) :: ['fission yeast']


abstract: BACKGROUND: The aims of this cohort study were to assess the survival of @entity130 @entity1 treated in a general intensive care unit (ICU) and to evaluate the @entity697 ( @entity697 ) II, maximum sequential organ failure assessment (SOFA) score, injury severity score (ISS), age, sex and severe @entity542 as predictors of 30-day mortality. METHODS: Three hundred and twenty-five adult @entity1 admitted during 1998-2003 were evaluated retrospectively with update of survival data in January 2005. Kaplan-Meier statistics and Cox proportional hazards regression were used to study survival and to assess predictors of mortality, respectively. RESULTS: The 30-day mortality was 16.9%, ICU mortality 13.8% and hospital mortality 17.8%. Long-term survival (observation time, 1-7 years) was 77.8%. After 3.5 years, mortality was the same as for the background population. Severe @entity542 was the main cause of @entity204 and increased the risk of 30-day mortality 2.4-fold. In addition, @entity697 II and an age above 50 years proved to be significant predictors of mortality in a multivariate analysis. Sex was not associated with mortality, and ISS and the maximum SOFA score were significant predictors in univariate analyses only. CONCLUSION: Reduced long-term survival was observed up to 3.5 years after @entity131 . The 30-day mortality was strongly related to severe @entity542 , @entity697 II and an age above 50 years. These variables may be useful as predictors of mortality, and may contribute to risk adjustment of this subset of @entity130 @entity1 when treatment results from different centres are compared.

title: XXXX @entity1 in the intensive care unit: short- and long-term survival and predictors of 30-day mortality.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['acute injury']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['simplified acute physiology score', 'SAPS']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury']

answer: @entity130 :: (MESH:D014947,Disease) :: ['Trauma']


abstract: UNASSIGNED: @entity40807 (NF) is one of the main aporphine alkaloids existing in the traditional Chinese medicine Folium Nelumbinis (lotus leaves). Modern pharmacological studies have demonstrated that NF has a broad spectrum of bioactivities, such as anti- @entity778 and anti-hyperlipidemic effects, and has been recommended as a leading compound for new drug development. However, the metabolites and biotransformation pathway of NF in vivo have not yet been comprehensively investigated. The present study was performed to identify the metabolites of NF for exploring in vivo fates. @entity35 plasma and urine samples were collected after oral administration and prepared by liquid-liquid extraction with @entity1046 . A method based on ultra fast liquid chromatography with tandem mass spectrometry was applied to identify the metabolites. Q1 (first quadrupole) full scan combined with multiple reaction monitoring (MRM) survey scan were used for the detection of metabolites. MRM-information dependent acquisition (IDA) of enhanced product ions (MRM-IDA-EPI) was used for the structural identification of detected metabolites. A total of ten metabolites were identified, including phase I (demethylation, oxidation and dehydrogenation) and phase II (glucuronidation, sulfation and @entity2041 ) biotransformation products. In which, demethylation is the main metabolic pathway of NF in the body. The results can help to better understand the disposition and pharmacological mechanism of NF in the body. This article is protected by copyright. All rights reserved.

title: Metabolism profiles of XXXX in @entity35 by using ultra fast liquid chromatography with tandem mass spectrometry.

entities_list: @entity1046 :: ('MESH:C007650', 'Chemical') :: ['ethyl acetate']

entities_list: @entity40807 :: ('MESH:C008692', 'Chemical') :: ['Nuciferine']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

answer: @entity40807 :: (MESH:C008692,Chemical) :: ['nuciferine']


abstract: BACKGROUND: Several methods have been developed to improve the efficacy of mechanical resuscitation, because organ perfusion achieved with conventional manual resuscitation is often insufficient. In animal studies, phased chest and abdominal compression-decompression resuscitation by use of the Lifestick device has resulted in a better outcome compared with that of conventional resuscitation. In end-of-life @entity1 , an increased coronary perfusion pressure was achieved. The aim of the present study was to determine the feasibility, safety, and efficacy of the Lifestick compared with conventional resuscitation in @entity1 with @entity1164 . METHODS AND RESULTS: The crews of 4 mobile intensive care units, staffed by an emergency physician and a paramedic, were trained to use the device. Fifty @entity1 were randomized by sealed envelopes to either Lifestick (n=24) or conventional (n=26) resuscitation. No differences were found regarding demographic and logistical conditions between the groups. Nineteen of the @entity1 (73%) with conventional resuscitation had @entity2224 , 13 of whom survived to hospital admission (no survivals with other @entity943 ) and 7 were discharged. In contrast, in the Lifestick-CPR group, only 9 @entity1 had @entity2224 (38%; P=<0.02; OR, 2.5; 95% CI, 0.6 to 10.6). Four of these 9 @entity1 and 5 of 15 @entity1 with other @entity943 survived to hospital admission, but none survived to hospital discharge. Autopsy in a subgroup of @entity1 who died at the scene revealed @entity130 with Lifestick than with conventional resuscitation. CONCLUSION: Lifestick resuscitation is feasible and safe and may be advantageous in @entity1 with @entity1167 or pulseless electric activity.

title: Phased chest and abdominal compression-decompression versus conventional cardiopulmonary resuscitation in out-of-hospital XXXX .

entities_list: @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden nontraumatic out-of-hospital cardiac arrest']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmias']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['less injuries']

answer: @entity1167 :: (MESH:D006323,Disease) :: ['cardiac arrest']


abstract: PURPOSE: This study aimed to evaluate the mid-term outcomes of single-stage modified anterior sagittal anorectoplasty (ASARP) for @entity2463 with @entity292 . METHOD: Twenty-six @entity1 with @entity14592 underwent single-stage modified sphincter-saving ASARP between January 2008 and December 2012. The ages of the @entity1 at the time of operation ranged from 1  month to 5.1  years. Standard ASARP procedure was modified to avoid the incision of the external sphincter complex. Instead a potential tunnel was created through the center of external sphincter complex under the endoscopic guidance. The @entity1 were evaluated for fecal continence and complications. RESULT: Modified ASARP was successfully performed in all @entity1 . The mean operation time was 52.2      3.5  min (range 47-61  min). The operative @entity190 was minimal. There was no operative complication. @entity2737 occurred in 3 @entity1 (3/26, 11.5  %). All @entity1 were followed up for 4.2      1.5  years (range 2-6  years). No @entity1 developed @entity1241 . Three @entity1 (3/26, 11.5  %) had soiling once or twice per week. Four @entity1 (4/26, 15.4  %) had @entity1142 amenable to diet management. Mucosal prolapse occurred in 1 @entity1 (1/26, 3.8  %). There was no recurrence of @entity292 , @entity850 or anterior displacement of the neorectum. CONCLUSION: Mid-term results show that single-stage modified ASARP is an effective and safe option for @entity1 with @entity2463 and @entity292 .

title: The management of XXXX with @entity292 : a single-stage modified anterior sagittal anorectoplasty.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity2463 :: ('MESH:C537771', 'Disease') :: ['anorectal malformation']

entities_list: @entity2737 :: ('MESH:D014946', 'Disease') :: ['Wound infection']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['vestibular fistula', 'fistula', 'congenital vestibular fistula']

entities_list: @entity14592 :: ('MESH:D001006', 'Disease') :: ['congenital imperforate anus and vestibular fistula']

entities_list: @entity1241 :: ('MESH:D005242', 'Disease') :: ['fecal incontinence']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['anal stenosis']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

answer: @entity2463 :: (MESH:C537771,Disease) :: ['anorectal malformation']


abstract: PURPOSE: In premenopausal @entity1 , @entity2588 contributes to @entity409 . It is unknown whether this vascular functional change is associated with vascular structural change. METHODS: This study examined regional and systemic vascular structure and function to gain insight into subclinical @entity731 risk in 10 @entity2587 , 18 @entity2587 , and 15 recreationally active controls. @entity384 ( @entity384 ) and low flow mediated constriction (L-FMC) were used to measure global endothelial function. Carotid-femoral pulse wave velocity ( @entity122 ) was used to measure @entity2333 . Doppler-ultrasound of the superficial femoral artery (SFA) was used to assess @entity121 ( @entity121 ) and vessel diameter as indicators of @entity6980 . RESULTS: Amenorrheic athletes had significantly lower @entity384 adjusted for shear stimulus (6.9      1.3%) compared with @entity2587 (11.0      1.0%) and controls (11.0      1.1%, p  =  0.05). Brachial L-FMC (-1.8      4.3%) and aortic @entity122 (5.0      1.0  m/s) of @entity2587 were similar to  those of @entity2587 (L-FMC,  -1.6      4.6%; @entity122 , 4.6      0.5  m/s) and controls (L-FMC,  -1.5      2.8%, p  =  0.98; @entity122 , 5.4      0.7  m/s, p  =  0.15). SFA diameters were similar in @entity2587 (5.7      0.7  mm) and @entity2587 (5.7      0.7  mm), but @entity2587 had larger SFA diameters compared with controls (5.1      0.6  mm, p  =  0.04). In @entity2587 , SFA @entity121 (0.31      0.03  mm) was similar to that of @entity2587 (0.35      0.07  mm) but significantly thinner compared to that of controls (0.38      0.06, p  =  0.01). CONCLUSION: @entity455 in female @entity2587 is not systemic. Parenthetically, @entity2588 may not prevent favorable peripheral vascular structural adaptations to habitual exercise training.

title: Subclinical XXXX risk in endurance-trained premenopausal amenorrheic @entity1 .

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['Vascular dysfunction']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['IMT', 'intima-media thickness']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['FMD', 'brachial FMD', 'Brachial flow-mediated dilation']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction']

entities_list: @entity2587 :: ('MESH:D001265', 'Disease') :: ['eumenorrheic athletes', 'amenorrheic athletes']

entities_list: @entity6980 :: ('MESH:D066253', 'Disease') :: ['vascular remodeling']

entities_list: @entity2333 :: ('MESH:D001018', 'Disease') :: ['aortic stiffness']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic']

entities_list: @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']

answer: @entity731 :: (MESH:D050197,Disease) :: ['atherosclerotic']


abstract: BACKGROUND: @entity955 ( @entity955 ) ablation is superior to pharmacologic therapy in achieving maintenance of normal sinus rhythm in selected @entity1 populations. However, the procedure is resource intensive, and repeat ablations are sometimes required. We examined the predictors and trends of repeat ablation using a large national administrative claims database. METHODS: Privately insured and Medicare Advantage @entity1 who underwent catheter ablation for @entity955 between January 1, 2004, and September 30, 2014, were included in the study. The primary outcome was repeat @entity955 ablation during enrollment. We examined the associations between repeat ablation and @entity1 demographics (age, gender, socioeconomic demographics), comorbid conditions (CHA2DS2-Vasc score and Charlson index), and year of the index ablation. Cox proportional hazard models were used to identify predictors of repeat ablation. RESULTS: We included 8,648 adult @entity1 in the analysis. Median age was 61.0 (interquartile range [IQR] 54-68) years, and 70.9% were @entity1 . Median follow-up was 1.1 (IQR 0.5-2.3) years. A total of 1,263 @entity1 underwent repeat ablation (14.6%) over a total of 14,280 @entity1 -years (12.1% at 1 year). The hazard ratio (HR) for repeat ablation was higher in younger @entity1 (HR 0.75 [0.61-0.91; P < .01] for age 65-75 and 0.55 [0.4-0.75; P < .001] for age >= 75 compared with age 18-54), those with higher household income (HR 1.24 [1-1.54; P < .05] for household income >=  100,000 compared with household income < 40,000), @entity1 treated in the south (HR 1.15 [1-1.31]; P < .05), and those on antiarrhythmic medications (HR 1.15 [1.01-1.31]; P < .05). In particular, younger @entity1 (ages 18-54 years) continued to undergo repeat ablations over the entire follow-up period, and the cumulative rate was approximately 40% among those followed for 5 years. Clinical characteristics including those included in the CHA2DS2-Vasc score and Charlson index did not predict likelihood of repeat ablation. The rate of repeat ablation remained constant over the available follow-up. CONCLUSION: Approximately 1 in 8 @entity1 treated with catheter ablation for @entity955 will undergo a second procedure within 1 year, although the rate is as high as 40% in young @entity1 at 5 years. The rate of repeat ablation appears to be associated with demographic characteristics (younger age and higher household income) rather than medical comorbidities.

title: Trends and predictors of repeat catheter ablation for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'person', 'men']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['Atrial fibrillation', 'AF']

answer: @entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']


abstract: BACKGROUND: Surgical implantation of recombinant @entity1 @entity1841 (rhBMP-2) in an absorbable collagen sponge carrier ( @entity12300 ) significantly enhances bone regeneration in horizontal alveolar defects; however, sufficient quantities of bone for implant dentistry are not routinely obtained. PURPOSE: The objective of this proof-of-principle study was to evaluate the potential of a space-providing macroporous expanded @entity736 (ePTFE) device to control volume and geometry of rhBMP-2/ @entity12300 -induced @entity604 . MATERIALS AND METHODS: Bilateral critical-size supra-alveolar periimplant defects were created in four Hound-Labrador mongrel @entity235 . Two turned and one surface-etched 10 mm @entity702 dental implants were placed 5 mm into the surgically reduced @entity133 creating 5 mm supra-alveolar defects. rhBMP-2/ @entity12300 (0.4 mg rhBMP-2) was placed around the exposed dental implants. Additionally, one jaw quadrant in each animal was randomly assigned to receive the dome-shaped macroporous ePTFE device. Mucoperiosteal flaps were advanced for primary wound closure. The animals were euthanized at 8 weeks post surgery for histometric analysis. RESULTS: The space-providing macroporous ePTFE device defined the volume and geometry of rhBMP-2/ @entity12300 -induced bone formation, whereas bone formation at sites receiving rhBMP-2/ @entity12300 alone varied considerably. Vertical @entity79 at turned dental implants averaged (+/-SD) 4.7 +/-0.2 mm at sites receiving @entity12300 and the ePTFE device compared with 3.5 +/-0.9 mm at sites receiving rhBMP-2/ @entity12300 only. The corresponding values for rhBMP-2/ @entity12300 -induced bone area were 9.6 +/- 0.7 mm2 and 7.5 +/-6.2 mm2. There was a highly significant correlation between induced bone area and the space provided by the ePTFE device (p <.001). There was no difference in induced bone density or bone-implant contact between the two technologies. These observations were consistent with those observed at surface-etched dental implants. CONCLUSIONS: The data from this study suggest that a space-providing macroporous ePTFE device defines rhBMP-2/ @entity12300 -induced @entity133 to provide adequate bone quantities for implant dentistry. The dental implant surface technology does not appear to substantially influence bone formation.

title: Space-providing expanded @entity736 devices define @entity133 at dental implants induced by recombinant XXXX @entity1841 in an absorbable collagen sponge carrier.

entities_list: @entity1841 :: ('650', 'Gene') :: ['bone morphogenetic protein 2']

entities_list: @entity604 :: ('MESH:D016301', 'Disease') :: ['alveolar bone augmentation']

entities_list: @entity133 :: ('MESH:D002282', 'Disease') :: ['alveolar augmentation', 'alveolar ridge']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone gain']

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium']

entities_list: @entity736 :: ('CHEBI:53251', 'Chemical') :: ['polytetrafluoroethylene']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: UNASSIGNED: Increasing results suggest microRNAs (miRNAs) could function important roles in @entity5 progression. miR-30a-5p is downregulated in variety of @entity5 and acts as a @entity5 suppressing gene. The functions and molecular mechanisms of miRNA-30a-5p in @entity157 ( @entity157 ) remain unclear. In the present study, quantitative real-time PCR (qRT-PCR) was used to detect miR-30a-5p expression in 16 pairs of @entity157 and their adjacent non-cancerous tissues and @entity157 cell lines. By overexpression of miRNA-30a-5p, CCK-8 and colon formation assay were used to evaluate cell growth and flow cytometry to evaluate cell apoptosis. Western blot was used to test protein expression. And potential mechanisms were analyzed with luciferase activity assay. In vivo @entity5 growth was observed with @entity19 . Our results showed that miR-30a-5p expression in @entity157 tissues was significantly lower compared to adjacent non-cancerous liver tissues, and lower miR-30a-5p expression was also observed in @entity157 cell lines compared to normal liver cell. Luciferase assay showed that @entity60789 ( @entity60789 ) mRNA was a direct target of miR-30a-5p. A significant reverse correlation between miR-30a-5p and @entity60789 in @entity96 tissues was observed. miR-30a-5p overexpression in @entity157 cells significantly inhibited cell proliferation, colon formation, and induced apoptosis while @entity60789 overexpression reversed growth inhibition and apoptosis induction of miRNA-30a-5p in @entity157 cells. miRNA-30a-5p upregulated phosphatase and tensin homolog ( @entity2370 ) protein expression and thus inhibited @entity1994 activating by targeting @entity60789 . miRNA-30a-5p also significantly inhibited @entity5 growth in vivo. Our results suggest that underexpression of miR-30a-5p might function as a @entity5 suppressing miRNA by directly targeting @entity60789 in @entity157 and is therefore a potential candidate biomarker for @entity157 targeting therapy.

title: Overexpression of microRNA-30a-5p inhibits @entity96 cell proliferation and induces apoptosis by targeting @entity60789 / @entity2370 / XXXX pathway.

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer', 'malignant tumor', 'HepG2 tumor']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

answer: @entity1994 :: (11651(Tax:10090),Gene) :: ['AKT']


abstract: To determine the overall survival and @entity344 for @entity1 treated with salvage definitive chemo-radiotherapy after primary surgery for locoregional relapse of @entity189 . A retrospective review of 525 @entity1 who had a resection for oesophageal or oesophagogastric @entity189 at Princess Alexandra Hospital identified 14 @entity1 treated with salvage definitive radiotherapy or chemo-radiotherapy, following localized recurrence of their disease. We analysed the @entity1 and treatment characteristics to determine the median overall survival as the primary end point. @entity344 was examined to determine if increased @entity137 occurred when the stomach was irradiated within the intrathoracic radiotherapy field. The median overall survival for @entity1 treated with curative intent using salvage definitive chemo-radiotherapy was 16 months and the 2-year overall survival is 21%. One @entity1 is in clinical remission more than 5 years after therapy. Age <60 years old and nodal recurrence were favourable prognostic factors. Treatment compliance was 93% with only one @entity1 unable to complete the intended schedule. Fourteen per cent of @entity1 experienced grade 3 or 4 @entity344 . Salvage definitive chemo-radiotherapy should be considered for good performance status @entity1 with @entity189 who have a locoregional relapse after primary surgery. The schedule is tolerable with low @entity137 and an acceptable median survival.

title: Salvage definitive chemo-radiotherapy for locally recurrent XXXX after primary surgery: retrospective review.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma', 'oesophageal carcinoma']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity', 'Gastrointestinal toxicity']

answer: @entity189 :: (MESH:D002277,Disease) :: ['oesophageal carcinoma']


abstract: PURPOSE: The impact of intraoperative @entity7048 on postoperative @entity410 after elective repair of an @entity438 was evaluated. METHODS: Chart review of a prospectively accrued database was performed for @entity1 admitted from January 1, 2003, through December 31, 2013. @entity1 were included in the study if they underwent elective repair of an unruptured @entity439 with surgical clipping or wrapping. The primary objective was to determine if the use of @entity7048 increased @entity1 ' odds of having a @entity410 within six hours of surgical intervention. Univariate comparisons were conducted on all variables for @entity1 who received @entity7048 and @entity1 who were treated with other antibiotics. Multivariable logistic regression was performed to assess the impact of @entity7048 administered intraoperatively on postoperative @entity410 , while accounting for other covariates. RESULTS: Of the 520 @entity1 included, 53 (10.2%) @entity1 developed @entity410 within six hours after surgery. A total of 439 (84.4%) @entity1 received @entity7048 intraoperatively. There were no differences in baseline characteristics between the @entity1 who received @entity7048 compared with those who did not. The frequency of @entity410 did not significantly differ between @entity1 treated with @entity7048 versus other antibiotics (11.2% versus 4.9%, respectively; p = 0.08). Multivariable regression revealed that the use of @entity7048 did not increase the odds of having a @entity410 postoperatively compared with @entity1 treated with other antibiotics (odds ratio, 2.4; 95% confidence interval, 0.82-7.15). CONCLUSION: No relationship was found between the intraoperative use of @entity7048 and the development of @entity410 during the six hours after the repair of unruptured @entity438 .

title: Impact of intraoperative @entity7048 on postoperative XXXX after elective repair of @entity438 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity7048 :: ('MESH:D002437', 'Chemical') :: ['cefazolin']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['unruptured cerebral aneurysm', 'cerebral aneurysms']

answer: @entity410 :: (MESH:D012640,Disease) :: ['seizures']


abstract: Aptamers, that exist naturally in living cells as functional elements and can switch nonfluorescent natural targets to fluorophores, are very useful in developing highly sensitive and selective biosensors and screening functional agents. This work demonstrates that @entity1 telomeric G-quadruplex (HTG) can serve as a potential fluorophore-switching aptamer (FSA) to target a natural @entity23386 . We found that, among the G-quadruplexes studied here and the various structurally similar alkaloids including @entity34685 (EPI), @entity7652 (BER), @entity12598 ( @entity15409 ), @entity66040 (JAT), @entity34683 (COP), @entity68476 (WOR), @entity15391 (SAN), @entity668 (CHE), and @entity40273 (NIT), only the HTG DNA, especially with a 5'-TA-3' residue at the 5' end of the G-quadruplex tetrad (5'-TAG3(TTAG3)3-3', TA[Q]) as the minimal sequence, is the most efficient FSA to selectively light up the EPI fluorescence. Compared to the 5' end flanking sequences, the 3' end flanking sequences of the tetrad contribute significantly less to the recognition of EPI. The binding affinity of EPI to TA[Q] (Kd = 37 nM) is at least 20 times tighter than those of the other alkaloids. The steady-state absorption, steady-state/time-resolved fluorescence, and NMR studies demonstrate that EPI most likely interact with the 5' end flanking sequence substructure beyond the core [Q] and the G-quadruplex tetrad in a much more specific manner than the other alkaloids. The highly selective and tight binding of EPI with the FSA and significantly enhanced fluorescence suggest the potential development of a selective EPI sensor (detection limit of 10 nM). More importantly, EPI, as the brightest FSA emitter among the alkaloids, can also serve as an efficient conformation probe for HTG DNA and discriminate the DNA G-quadruplex from the RNA counterpart. Furthermore, EPI can bind stoichiometrically to each G-quadruplex unit of long HTG DNA multimer with the most significant fluorescence enhancement, which has not been achieved by the previously reported probes. Our work suggests the potential use of EPI as a bioimaging probe and a therapeutic DNA binder.

title: Selective Lighting Up of @entity34685 Alkaloid Fluorescence by Fluorophore-Switching Aptamer and Stoichiometric Targeting of XXXX Telomeric DNA G-Quadruplex Multimer.

entities_list: @entity66040 :: ('MESH:C055785', 'Chemical') :: ['jatrorrhizine']

entities_list: @entity7652 :: ('MESH:D001599', 'Chemical') :: ['berberine']

entities_list: @entity23386 :: ('CHEBI:24921', 'Chemical') :: ['isoquinoline alkaloid']

entities_list: @entity668 :: ('MESH:C016299', 'Chemical') :: ['chelerythrine']

entities_list: @entity34685 :: ('MESH:C061432', 'Chemical') :: ['epiberberine']

entities_list: @entity34683 :: ('MESH:C034384', 'Chemical') :: ['coptisine']

entities_list: @entity12598 :: ('MESH:C005413', 'Chemical') :: ['palmatine']

entities_list: @entity15391 :: ('MESH:C005705', 'Chemical') :: ['sanguinarine']

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: BACKGROUND AND AIM: The purpose of this study was to describe the computed tomography (CT) findings of @entity2857 -treated @entity99 in @entity1 with @entity157 and to correlate the findings to the overall survival (OS). METHODS: Twenty-eight @entity2857 -treated @entity1 who had @entity157 ( @entity157 ) with viable @entity99 between August 2007 and February 2008 were enrolled in the study. Dynamic CT findings were analyzed with regard to the response of the @entity5 , based on the response evaluation criteria in solid @entity5 , version 1.1, and the attenuation values of the @entity5 during the late arterial and portal venous phases. Survival analyses according to early changes in the @entity5 were also performed. RESULTS: In all @entity1 , the @entity5 responses were stable disease or progressive disease on follow-up CT scans. Prior to the treatment, the mean attenuation values of the @entity5 were 93.0    20.0 Hounsfield unit (HU) at the late arterial phase, and 107.9    23.0 HU at the portal venous phase. On the first follow-up CT scans, the mean attenuation values of the late arterial and portal venous phases were 76.9    26.5 HU and 94.2    29.1 HU, respectively (P < 0.01). The median OS was better for the @entity1 with the response of stable disease than the @entity1 with progressive disease (P = 0.013). CONCLUSIONS: In @entity1 with advanced @entity157 who were treated by @entity2857 , the size of the @entity99 was not significantly reduced. However, the median survival was better for the @entity1 with the response of stable disease. The attenuation values of the @entity5 became lower after treatment, as compared to the baseline CT scans.

title: Computed tomography findings of @entity2857 -treated @entity99 in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'advanced hepatocellular carcinoma']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic tumors']

answer: @entity157 :: (MESH:D006528,Disease) :: ['advanced hepatocellular carcinoma']


abstract: UNASSIGNED: 2040 Background: @entity68820 is a novel @entity3907 that has demonstrated exceptional activity in @entity1 xenograft models when administered intravenously and orally. Preclinical studies of @entity68820 have shown antitumor activity in MDR-expressing and @entity1311 -resistant @entity5 . METHODS: This phase 1 ascending-dose study was performed to determine the safety and tolerability of orally administered @entity68820 given once every 21 days. Preliminary antitumor activity of @entity68820 was also examined. Key eligibility criteria included adult @entity1 with refractory solid @entity5 , good performance status (ECOG <=  2), and adequate hematologic, hepatic, and renal function. Plasma pharmacokinetic (PK) sampling was performed during the first cycle of therapy. RESULTS: 18 @entity1 (4 females, 14 males) were evaluated at 5 dose levels ranging from 25 to 75 mg/m(2). Treatment was well tolerated at the first 3 dose levels (25, 37, 50 mg/m(2)). Two @entity1 developed dose-limiting @entity137 (DLTs) at 75 mg/m(2) (1 @entity1 with grade 3 @entity1398 with @entity221 , another @entity1 had grade 4 @entity1398 with @entity221 ). Three @entity1 were treated at an intermediate dose level of 60 mg/m(2) without DLTs. Other common @entity137 included grade 1-2 fatigue and grade 1-2 @entity294 . Disease stabilization was seen in 4 @entity1 with the following @entity5 : mesothelioma (14 cycles), @entity511 (12 cycles), @entity4153 (10 cycles), and @entity263 (6 cycles). There was substantial interpatient variability in the PK parameters. @entity68820 was absorbed rapidly with mean Tmax less than 1 hour. Mean Cmax and AUC values generally increased in a dose-related manner. The elimination half-life ranged from 20-228 hours. CONCLUSIONS: @entity68820 can be safely administered orally once every 21 days up to a dose of 60 mg/m(2). The major DLT was @entity221 . Four @entity1 had disease stabilization. This study is ongoing to confirm 60 mg/m(2) as the maximum tolerated dose and to determine the oral bioavailability of @entity68820 . [Table: see text].

title: Phase 1 trial of oral @entity68820 in subjects with advanced XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity511 :: ('MESH:D002813', 'Disease') :: ['chondrosarcoma']

entities_list: @entity4153 :: ('MESH:D018288', 'Disease') :: ['small cell carcinoma']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever', 'fever']

answer: @entity5 :: (MESH:D009369,Disease) :: ['malignant solid tumors']


abstract: BACKGROUND: A descriptive cross-sectional study was carried out to assess the dental caries and @entity2520 status of elderly residing in old age homes of Madhya Pradesh, India. MATERIALS AND METHODS: The study was carried out on 599 elderly @entity1 residing in old age homes of Madhya Pradesh, India using cluster sampling methodology. The clinical findings were recorded using modified WHO Oral Health Assessment form (1997) to assess periodontal status as per community periodontal index, loss of attachment, WHO dentition status, and treatment needs. RESULTS: In the present study, the caries prevalence among dentate subjects was found among 41.9% of the dentate subjects and the mean decayed, missed, and filled teeth was found to be 8.28    4.779 with the mean number of decayed being 1.51. In the dentate population, 0% had healthy periodontal tissue, 0.26% had @entity548 , and 24.5% had calculus, 52.1% had shallow pockets and 23.1% had deep pockets as their highest score and this difference was statistically significant (P < 0.05). In the current study, 37.9% inmates were completely edentulous. This study also showed that as age advanced the prevalence increased from 23.1% to 55.4%. The difference was statistically significant (P < 0.05). CONCLUSION: The oral health status of elderly @entity1 was found to be poor. Hence, it is concluded from this study that @entity2524 is higher among the geriatric group residing in old age homes and is associated with many demographic and behavioral risk indicators.

title: Assessment of Dental Caries and XXXX Status among Elderly Residing in Old Age Homes of Madhya Pradesh.

entities_list: @entity2524 :: ('MESH:D016388', 'Disease') :: ['tooth loss']

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['periodontal disease']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

answer: @entity2520 :: (MESH:D010510,Disease) :: ['Periodontal Disease']


abstract: PURPOSE: The purpose of this study was to compare the outcomes of @entity1 treated with chemoradiotherapy with a complete clinical response followed by either a "watch and wait" strategy or a total mesorectal excision. METHODS: This was an observational retrospective study from a single institute. @entity1 with locally advanced @entity5 following chemoradiotherapy with a complete clinical response from January 1, 2007 to December 31, 2014 were included. RESULTS: The study population consisted of 18 @entity1 who opted for a "watch and wait" policy and 26 @entity1 who underwent radical surgery after achieving a complete clinical response. @entity1 had no documented treatment complications under the watch and wait policy, while 13 @entity1 who underwent radical surgery experienced significant morbidity. There were two local recurrences in the watch and wait group; both were treated with salvage resection and had no associated mortality. In the radical surgery group, 1 @entity1 showed an incomplete pathologic response (ypT0N1), and the remaining 25 @entity1 showed complete pathologic responses; 1 had a distant recurrence, which was managed non-operatively, and 2 @entity1 died of unrelated causes. The 5-year overall survival rate and median disease-free survival time were 100  % and 69.78  months in the watch and wait group and 92.30  % and 89.04  months in the radical surgery group. CONCLUSIONS: A watch and wait policy avoids the morbidity associated with radical surgery and preserves oncologic outcomes in our retrospective study from a single institute. It could be considered a therapeutic option in @entity1 with locally advanced @entity5 following chemoradiotherapy with a complete clinical response.

title: XXXX with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or "watch and wait".

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['rectal cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Rectal cancer']


abstract: BACKGROUND: Evidence implicated the diagnostic significance of microRNAs in whole urine/urine sediments in @entity189 of the bladder (UCB). However, the contaminated blood cells in @entity1 with haematouria significantly altered the expression profiles of urinary microRNA, influencing the test accuracy. METHODS: MicroRNA profiles of the urine supernatants of UCB @entity1 and controls without any @entity5 and profiles of malignant and corresponding normal mucosa tissues from the @entity1 were determined by microRNA microarray and compared to identify differentially expressed microRNAs. The differential expression was verified in the tissues of an independent @entity1 cohort by RT-qPCR. The diagnostic significance of selected microRNAs as biomarkers in the urine supernatant was investigated in the expanded cohorts. RESULTS: @entity31586 and microRNA-125b were down-regulated in the urine supernatants of UCB @entity1 . The degree of down-regulation was associated with the @entity5 grade. A diagnostic model was developed using a combined index of the levels of @entity31586 and microRNA-125b in the urine supernatant with a sensitivity of 86.7%, a specificity of 81.1% and a positive predicted value ( @entity2286 ) of 91.8%. Discriminating between high- and low-grade UCB, the model using the level of microRNA-125b alone exhibited a sensitivity of 81.4%, a specificity of 87.0% and a @entity2286 of 93.4%. CONCLUSIONS: The results revealed a unique microRNA expression signature in the urine supernatants of UCB @entity1 for the development of molecular diagnostic tests. An effective cell-free urinary microRNA-based model was developed using a combined index of the levels of @entity31586 and microRNA-125b to detect UCB with good discriminating power, high sensitivity and high specificity.

title: Cell-free urinary XXXX and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancy']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma']

answer: @entity31586 :: (407055,Gene) :: ['microRNA-99a']


abstract: OBJECTIVE: To evaluate the national patterns of urologic follow up after @entity1566 ( @entity1566 ) and the occurrence and predictors of urological complications. MATERIALS AND METHODS: This retrospective cohort study used a 5% sample of Medicare data 2007-2010. The minimum adequate urologic surveillance was defined as a urologist visit, serum @entity1011 evaluation, and upper urinary tract imaging study within the 2-year period. @entity1 were classified to their most severe complication in a multivariate linear regression model. RESULTS: Among the 7162 @entity1 with @entity1566 , the majority were functionally paraplegic (82.4%) and Caucasian (80.9%). Among them, 4.9% received no screening studies over the 2-year period; 70.5% received some, but not all screening; and 24.6% received all three screening tests. @entity1 traveled a mean of 21.3    27.5 miles to receive care. A total of 35.7% of @entity1 saw a urologist during the 2-year period; 48.6% had some form of upper tract evaluation, with the majority being computed tomography scans; and 90.7% had serum @entity1011 evaluation. Of all @entity1 , 35.8% had a minor complication during their 2-year follow up, 17.1% had a moderate complication, and 8.0% had a severe complication. In our prediction model, @entity1 factors that correlated with increased complications included male gender, African American race, @entity451 , and receiving some or all of the @entity1494 recommended screening. @entity1 ' distance of travel to their treating physician (urologist or physiatrist) did not affect the rate of complications. CONCLUSION: Urological complications are common in @entity1 with @entity1566 who receive Medicare. Most of these @entity1 with @entity1566 are not receiving even the minimum recommended surveillance for these urological complications.

title: Urological Surveillance and Medical Complications after XXXX in the United States.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['neurogenic bladder']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'SCI']

entities_list: @entity451 :: ('MESH:C536857', 'Disease') :: ['paraplegia']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['Spinal Cord Injury']


abstract: INTRODUCTION: @entity40934 -like @entity784 (SPTL-AB) and @entity784 ( @entity784 ) are rare @entity784 with varying clinical courses. There is no standard treatment, although chemotherapy and hematopoietic stem cell transplantation are commonly used. We describe results using @entity35406 for @entity1 and adults with these disorders. METHODS: We identified 15 @entity1 (12 adults, 3 @entity1 ) who were treated with @entity35406 between 2000 and 2010 from the Memorial Sloan-Kettering @entity5 Center @entity706 database, the @entity5 Center Registry, and the National @entity5 Institute (NCI) @entity706 database. There were 8 females and 7 males, with a median age of 45 years (range, 3 years to 85 years). All @entity1 had stage IV disease. Two of 15 and 4 of 15 @entity1 had documented @entity784 and SPTL-AB, respectively; others were presumed to have SPTL-AB. @entity35406 was administered at flat doses corresponding to 91 to 339 mg/m(2)/d. Two of 15 @entity1 received concurrent denileukin diftitox. Two @entity1 received @entity35406 as maintenance therapy and were not evaluable for response. RESULTS: Among those treated with @entity35406 alone, the overall response rate (ORR) was 82% (6/11 complete response [CR], 3/11 partial response [PR]). One of the 2 @entity1 treated with concomitant denileukin diftitox responded for an ORR of 10/13 (77%), including 54% CR and 23% PR. Median progression-free survival was 38.4 months; median duration of response was 26.3 months. Six @entity1 developed @entity1375 and 9 developed @entity407 ; one @entity1 developed dose-limiting @entity2298 . One pediatric @entity1 developed @entity1723 . CONCLUSIONS: In this retrospective series, @entity35406 showed a high response rate in SPTL-AB and @entity784 . It was generally well-tolerated with durable responses; therefore, @entity35406 represents a promising therapy for @entity1 and adults with these disorders.

title: @entity35406 is active against XXXX -like @entity784 in adult and pediatric populations.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism']

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia']

entities_list: @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia']

entities_list: @entity35406 :: ('MESH:C095105', 'Chemical') :: ['bexarotene', 'Bexarotene']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'pediatric lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Stanford Cancer', 'Cancer']

entities_list: @entity784 :: ('MESH:D016399', 'Disease') :: ['CGD-TCL', 'cutaneous gamma/delta T-cell lymphoma', 'T-cell lymphomas', 'T-cell lymphoma']

entities_list: @entity40934 :: ('MESH:C537503', 'Disease') :: ['Subcutaneous panniculitis']

entities_list: @entity1723 :: ('MESH:D003922', 'Disease') :: ['insulin-dependent diabetes mellitus']

answer: @entity40934 :: (MESH:C537503,Disease) :: ['subcutaneous panniculitis']